Komori
Genova (9341) · RiskDropped

Potential Losses Due to the Continuing and Prolonged Impact of COVID-19

First written in FY2023-Q3. 3 of 5 entries say "Mitigated", first in FY2024-Q1. Latest entry: FY2025.

5entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2023-Q3MitigatedFY2024-Q1 – FY2024-Q32023: 320232024: 120242025: 12025
Same theme, other companies
Risk of COVID-19 impacts on business activities, supply chains, demand and financial performanceA theme 1257 companies write about · 1269 as a headwind · 6 as a tailwind

The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 196 companies compared. The sentences above are computed from all 196.Comparing 200 of the theme's 1283 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2025DroppedAnnual report
    This annual securities report does not identify COVID-19 as a specific business-environment risk.
  2. FY2024-Q3MitigatedAnnual report

    「During the cumulative third quarter of the current consolidated fiscal year, as COVID-19 was brought under control, socioeconomic activity continued to normalize and travel and other movement, including inbound tourism, recovered. Domestic and international demand and economic activity were also beginning to regain momentum.」

    Describes the containment of the infectious disease, the normalization of socioeconomic activity, the recovery of travel and other movement, and the recovery of demand and economic activity.
  3. FY2024-Q2MitigatedAnnual report

    「During the cumulative second quarter of the current consolidated fiscal year, Japan's economy was reportedly recovering to 70% of pre-pandemic levels in terms of domestic and international travel and other movement, including inbound tourism, following the reclassification of COVID-19 as a Category V infectious disease and the easing of restrictions on activities. Economic activity was also beginning to regain momentum.」

    Describes the reclassification as a Category V infectious disease, the easing of restrictions on activities, the recovery of travel and other movement to 70% of pre-pandemic levels, and the recovery of economic activity.
  4. FY2024-Q1MitigatedAnnual report

    「As restrictions on activities were eased in response to the COVID-19 pandemic, the disease was reclassified as a Category V infectious disease. Domestic and international travel and other movement, including inbound tourism, showed signs of gradually recovering to pre-pandemic levels, and signs of a moderate recovery in economic activity were observed.」

    Describes the easing of restrictions on activities, the reclassification as a Category V infectious disease, and signs of recovery in travel and other movement and economic activity, indicating that the impact of the infectious disease on the business environment has eased.
  5. FY2023-Q3First statedAnnual report

    「The spread of COVID-19 is an event with broad effects on the economy and corporate activities, and although it is difficult to reasonably predict when it will subside or the extent of its impact, the company assumes that the effects will continue at least through the fiscal year ending March 2023 and will be limited from the fiscal year ending March 2024 onward. This assumption is highly uncertain, and if the resolution of the pandemic is delayed and its effects are prolonged, losses may arise in the future.」

    Indicates the potential for future losses if the impact takes longer to subside or becomes prolonged, while assuming the period over which the impact will continue.
Moved together

"Expanding Use of the Medical Platform and Growth in the Number of Contracts" moved the same way as this thread, in the same document, in 3 of its 5 moves.

332222★123456
  1. ★This thread
  2. 1Expanding Use of the Medical Platform and Growth in the Number of Contracts3×
  3. 2Development of an Online Medical Consultation System and New Products3×
  4. 3Providing Access to Appropriate Medical Information to Promote Healthy Life Expectancy2×
  5. 4Introduction of smart self-service payment and repeat-visit check-in machines and expansion of contracts2×
  6. 5Increase in Employee Headcount Accompanying Business Expansion2×
  7. 6Increase in Shares Outstanding and Capital Through the Exercise of Stock Acquisition Rights2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Genova yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Potential Losses Due to the Continuing and Prolonged Impact of COVID-19 | GENOVA,Inc. (9341) | Komori